384 related articles for article (PubMed ID: 16940797)
1. New molecular targeted therapies in thyroid cancer.
Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
[TBL] [Abstract][Full Text] [Related]
2. Targeting RET for thyroid cancer therapy.
Lanzi C; Cassinelli G; Nicolini V; Zunino F
Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
[TBL] [Abstract][Full Text] [Related]
3. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer.
Santoro M; Carlomagno F
Nat Clin Pract Endocrinol Metab; 2006 Jan; 2(1):42-52. PubMed ID: 16932252
[TBL] [Abstract][Full Text] [Related]
4. Targeting RET receptor tyrosine kinase activation in cancer.
Phay JE; Shah MH
Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
[TBL] [Abstract][Full Text] [Related]
5. Medullary thyroid cancer: molecular biology and novel molecular therapies.
Cakir M; Grossman AB
Neuroendocrinology; 2009; 90(4):323-48. PubMed ID: 19468197
[TBL] [Abstract][Full Text] [Related]
6. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
Akeno-Stuart N; Croyle M; Knauf JA; Malaguarnera R; Vitagliano D; Santoro M; Stephan C; Grosios K; Wartmann M; Cozens R; Caravatti G; Fabbro D; Lane HA; Fagin JA
Cancer Res; 2007 Jul; 67(14):6956-64. PubMed ID: 17638907
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy: a new hope for thyroid carcinomas.
Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of RET tyrosine kinase by SU5416.
Mologni L; Sala E; Cazzaniga S; Rostagno R; Kuoni T; Puttini M; Bain J; Cleris L; Redaelli S; Riva B; Formelli F; Scapozza L; Gambacorti-Passerini C
J Mol Endocrinol; 2006 Oct; 37(2):199-212. PubMed ID: 17032739
[TBL] [Abstract][Full Text] [Related]
10. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
Santarpia L; Ye L; Gagel RF
J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
[TBL] [Abstract][Full Text] [Related]
11. New targets and therapeutic approaches for endocrine malignancies.
Fassnacht M; Kreissl MC; Weismann D; Allolio B
Pharmacol Ther; 2009 Jul; 123(1):117-41. PubMed ID: 19374919
[TBL] [Abstract][Full Text] [Related]
12. Medullary thyroid cancer: therapeutic targets and molecular markers.
Ball DW
Curr Opin Oncol; 2007 Jan; 19(1):18-23. PubMed ID: 17133107
[TBL] [Abstract][Full Text] [Related]
13. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
14. BAY 43-9006 inhibition of oncogenic RET mutants.
Carlomagno F; Anaganti S; Guida T; Salvatore G; Troncone G; Wilhelm SM; Santoro M
J Natl Cancer Inst; 2006 Mar; 98(5):326-34. PubMed ID: 16507829
[TBL] [Abstract][Full Text] [Related]
15. New approaches to thyroid cancer.
Cohen EE
Clin Adv Hematol Oncol; 2012 Apr; 10(4):255-6. PubMed ID: 22706487
[No Abstract] [Full Text] [Related]
16. New therapies for dedifferentiated papillary thyroid cancer.
Fallahi P; Mazzi V; Vita R; Ferrari SM; Materazzi G; Galleri D; Benvenga S; Miccoli P; Antonelli A
Int J Mol Sci; 2015 Mar; 16(3):6153-82. PubMed ID: 25789503
[TBL] [Abstract][Full Text] [Related]
17. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
18. Molecular targeted therapy for neuroendocrine tumors.
Yao JC; Hoff PM
Hematol Oncol Clin North Am; 2007 Jun; 21(3):575-81; x. PubMed ID: 17548041
[TBL] [Abstract][Full Text] [Related]
19. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.
Kojic KL; Kojic SL; Wiseman SM
Expert Rev Anticancer Ther; 2012 Mar; 12(3):345-57. PubMed ID: 22369326
[TBL] [Abstract][Full Text] [Related]
20. RET inhibition: implications in cancer therapy.
Borrello MG; Ardini E; Locati LD; Greco A; Licitra L; Pierotti MA
Expert Opin Ther Targets; 2013 Apr; 17(4):403-19. PubMed ID: 23461584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]